Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) EBITDA (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBITDA for 4 consecutive years, with -$19.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 47.39% to -$19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.9 million through Dec 2025, up 92.19% year-over-year, with the annual reading at -$9.9 million for FY2025, 92.19% up from the prior year.
  • EBITDA for Q4 2025 was -$19.2 million at Century Therapeutics, up from -$34.4 million in the prior quarter.
  • The five-year high for EBITDA was $76.5 million in Q1 2025, with the low at -$39.5 million in Q1 2022.
  • Average EBITDA over 4 years is -$25.2 million, with a median of -$31.5 million recorded in 2022.
  • The sharpest move saw EBITDA fell 24.37% in 2023, then skyrocketed 369.41% in 2025.
  • Over 4 years, EBITDA stood at -$30.5 million in 2022, then dropped by 24.37% to -$38.0 million in 2023, then increased by 3.89% to -$36.5 million in 2024, then soared by 47.39% to -$19.2 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$19.2 million, -$34.4 million, and -$32.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.